Skip to main content
Premium Trial:

Request an Annual Quote

Symyx Partners with Simulations Plus on ADMET Database

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Drug research software maker Simulations Plus will use Symyx's Metabolite database to develop and improve a predictive modeling system for in silico metabolic properties, Symyx said today.

Simulations Plus plans to develop a new module used for predictive modeling of ADMET (absorption, distribution, metabolism, excretion, and toxicity) applications.

The new system will be incorporated into a new Symyx Metabolite module, which will be offered as part of the Simulations Plus ADMET Predictor software later this year.

The Simulations Plus software is used by drug research organizations to improve compound design, lower the cost of experiments, and reduce the number of late product failures.

The Symyx Metabolite software covers xenobiotic transformations and metabolic schemes from publications, and non-proprietary studies from new drug applications published by the Food and Drug Administration.

"One of our explicit aims is the development of a predictive mathematical model that will be capable of identifying specific sites of metabolism," Simulations Plus CEO and Chairman Walt Woltosz said in a statement.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.